Takeda Pharmaceuticals has appointed John Boslego as senior vice president and head of development for its global vaccine business unit, effective from December 1.
He succeeds Ralf Clemens, who has served in the role since the launch of Takeda’s vaccine business division in January 2012.
Boslego will be responsible for accelerating global vaccine development activities with a focus on lead development programmes for dengue, norovirus and seasonal influenza. He will report to Rajeev Venkayya, president of Takeda’s global vaccine business unit.
Commenting on the appointment, Venkayya said: “John brings a wealth of vaccine development and global health experience to Takeda at an important time.
“He takes the helm of an outstanding development team that was built by Ralf Clemens and I have the utmost confidence in their ability to deliver our exciting pipeline.”
Boslego has work in vaccine clinical research and development for over 40 years and was most recently director of the vaccine development global programme at PATH, where he built a vaccine development organisation and advanced vaccine development against illnesses including rotavirus, polio and meningococcus.
He has also served as executive director of biologics, clinical research at Merck & Co and prior to this, directed the Armed Forces Research Institute of Medical Sciences (AFRIMS) in Bangkok, Thailand.